北大医药新主面临待解后遗症

Core Viewpoint - The new controlling shareholder Xu Xiren has completed a management reshuffle at Peking University Pharmaceutical, but the company faces significant operational challenges and potential revenue loss due to the termination of key contracts with its largest client, Peking University International Hospital [2][5][6]. Group 1: Management Changes - After taking control, Xu Xiren appointed himself as CEO and made significant changes to the management team, including the resignation of long-standing executives [3][12]. - The previous management team, which had successfully turned around the company's performance, has largely departed, raising concerns about continuity and stability [12][14]. Group 2: Operational Challenges - Peking University Pharmaceutical is experiencing disruptions due to historical issues related to employee benefits, leading to protests from retired staff that have affected administrative operations [5]. - The company has relied heavily on its relationship with Peking University International Hospital, which accounted for approximately 78% of its drug distribution revenue in 2024 [15][16]. Group 3: Financial Implications - The termination of the contract with Peking University International Hospital, which was valued at 12 billion yuan over three years, poses a risk of losing approximately 910 million yuan in annual sales and 36.66 million yuan in net profit starting in 2025 [19][22]. - Despite the termination, the company had previously indicated a potential future collaboration worth 40.5 million yuan, but this has been contradicted by recent statements confirming the end of all cooperation [20][22].